Robeco Institutional Asset Management B.V. Sells 95,039 Shares of Zoetis Inc. (NYSE:ZTS)

Robeco Institutional Asset Management B.V. trimmed its stake in Zoetis Inc. (NYSE:ZTS - Free Report) by 14.3% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 568,472 shares of the company's stock after selling 95,039 shares during the period. Robeco Institutional Asset Management B.V. owned 0.13% of Zoetis worth $92,621,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. State Street Corp lifted its stake in shares of Zoetis by 0.5% in the third quarter. State Street Corp now owns 19,779,344 shares of the company's stock worth $3,864,488,000 after buying an additional 95,856 shares during the last quarter. Geode Capital Management LLC raised its holdings in Zoetis by 1.8% in the 3rd quarter. Geode Capital Management LLC now owns 10,427,760 shares of the company's stock worth $2,030,813,000 after acquiring an additional 185,364 shares during the period. Mizuho Securities USA LLC lifted its position in Zoetis by 13,726.9% during the 3rd quarter. Mizuho Securities USA LLC now owns 4,865,000 shares of the company's stock worth $950,524,000 after acquiring an additional 4,829,815 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in Zoetis by 5.3% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 3,896,106 shares of the company's stock valued at $761,221,000 after acquiring an additional 194,542 shares during the period. Finally, Clearbridge Investments LLC grew its position in shares of Zoetis by 5.8% in the second quarter. Clearbridge Investments LLC now owns 3,044,384 shares of the company's stock valued at $527,774,000 after purchasing an additional 166,517 shares during the last quarter. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

ZTS has been the subject of several recent analyst reports. UBS Group started coverage on Zoetis in a research note on Monday, December 9th. They set a "neutral" rating and a $196.00 target price for the company. Leerink Partnrs upgraded shares of Zoetis to a "strong-buy" rating in a research note on Monday, December 2nd. Morgan Stanley cut their target price on shares of Zoetis from $248.00 to $243.00 and set an "overweight" rating for the company in a research note on Wednesday. JPMorgan Chase & Co. raised their price target on shares of Zoetis from $225.00 to $230.00 and gave the stock an "overweight" rating in a research report on Friday, October 11th. Finally, Stifel Nicolaus cut their price objective on shares of Zoetis from $210.00 to $180.00 and set a "buy" rating for the company in a research report on Tuesday, January 7th. One research analyst has rated the stock with a hold rating, ten have given a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, Zoetis currently has a consensus rating of "Buy" and a consensus target price of $215.00.

Zoetis Price Performance

Shares of ZTS stock traded down $1.90 during trading hours on Friday, hitting $170.81. The company had a trading volume of 2,630,702 shares, compared to its average volume of 2,468,532. The company has a debt-to-equity ratio of 1.26, a quick ratio of 2.27 and a current ratio of 3.69. The firm has a market capitalization of $77.06 billion, a price-to-earnings ratio of 32.11, a PEG ratio of 2.70 and a beta of 0.89. Zoetis Inc. has a 12 month low of $144.80 and a 12 month high of $200.53. The firm's fifty day moving average is $169.62 and its 200 day moving average is $179.49.

Zoetis (NYSE:ZTS - Get Free Report) last announced its quarterly earnings results on Monday, November 4th. The company reported $1.58 earnings per share for the quarter, beating analysts' consensus estimates of $1.46 by $0.12. Zoetis had a return on equity of 51.98% and a net margin of 26.55%. The firm had revenue of $2.40 billion for the quarter, compared to analysts' expectations of $2.29 billion. During the same period in the prior year, the business posted $1.36 earnings per share. The business's revenue was up 11.6% compared to the same quarter last year. On average, sell-side analysts predict that Zoetis Inc. will post 5.9 EPS for the current fiscal year.

Zoetis Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, March 4th. Shareholders of record on Tuesday, January 21st will be given a $0.50 dividend. The ex-dividend date is Tuesday, January 21st. This is a positive change from Zoetis's previous quarterly dividend of $0.43. This represents a $2.00 dividend on an annualized basis and a yield of 1.17%. Zoetis's payout ratio is 37.59%.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.